pharma

Tell me about Eagle. The CEO resigned last year, the CFO this year. What is going on there? Is it normal?

Hello everyone, I'm being offered a VS2 role in the pharma side of the Bayer business and was wondering how senior is this role within the organization compared to their internal structure? - What are the grades starting from lowest to the highest grades? - Is VS2 a director level role? I...

What's the outlook for DBU in PC in terms of pipeline, job security etc? And base salary for someone with 3 years field experience?

Hey yall, I know this question comes up alot but pharma or med-device. I just recieved a Pharma offer but also am in the 2 round of interviews with Stryker for a role. I am torn on what to do. I have one year in B2B sales, and really want to get into Medical Device. I came across a Pharma job...

In an exclusive interview with the AlphaStreet, ImmunoGen Inc (NASDAQ: IMGN) executive chief Mark Enyedy spoke about the company's product strategy, pipeline, and more. The pharma sector continues to be running on the tight budgets due to disruptive COVID-19 pandemic. However, ImmunoGen...

Hello, Dear forum members, While I am finishing my thesis, I am in lack of answers for my 5 min study and particularly from shareholders & biotech employes. I would appreciate a lote any help you could provide!! Pharmacist and student of Essec, I am finishing my master's thesis on the subject...

Merck surpassed analysts’ expectations for revenue and earnings in the third quarter of 2019, sending the shares climbing 2.5% in premarket hours on Tuesday. Worldwide sales rose 15% year-over-year to $12.4 billion, beating estimates of $11.6 billion. Excluding foreign exchange impacts, sales...

Eli Lilly surpassed earnings expectations for the third quarter of 2019 but revenues came in shy of estimates. Total revenue grew 3% year-over-year to $5.47 billion, but fell short of estimates of $5.5 billion. Revenues grew 4% excluding foreign currency impacts. Revenue growth was driven by an...

Abbott Laboratories’ third quarter 2019 earnings came in line with the market’s projections, while sales missed the expectations. The pharma company reported adjusted EPS of $0.84 on sales of $8.08 billion. Wall Street had forecasted Abbott to post earnings of $0.84 on sales of $8.11 billion...

Earnings of Johnson & Johnson increased and topped the Street view in Q3 helped by a 2% growth in sales. Encouraged by the positive outcome, the management revised up its full-year earnings and sales outlook. The company’s stock gained following the announcement. Read More

Bristol-Myers-Squibb announced that Amgen will acquire Celgene’s Otezla business for $13.4 billion in a cash transaction. Bristol-Myers now expects to complete the pending merger with Celgene by the end of 2019. For More:

Here's another good show by Alexion Pharma...! June-quarter financial results surpassed the consensus estimates of Wall Street analysts, powered by flagship SOLIRIS. No doubt, it's a much-needed boost for Alexion. Taking a cue from the impressive results, CEO Ludwig Hantson upgraded the outlook...

Biogen reported second-quarter earnings that surpassed Wall Street expectations. The company reported adjusted earnings of $9.15 per share, way ahead of the street projection of $7.53 per share. On a GAAP basis, earnings grew 88% to $7.85 per share. Revenue grew 8% to $3.62 billion, surpassing...

Novartis on Thursday surprised Wall Street by reporting a year-over-year increase in net earnings in Q2, helped by higher sales and a one-time divestment gain. The company said its earnings grew 14% to $1.34 per share, even as analysts were anticipating a decline. Riding on the strong sales of...

I am hearing that this company might be the next big thing. Anyone?

JNJ kicked off pharma earnings as it posted its first-quarter 2019 earnings on Tuesday, April 16, before the opening bell. Reported revenue for the quarter barely changed — inching just 0.1% higher — at $20 billion, while net earnings slipped 14% to $3.7 billion. On a diluted basis, earnings...

What do startups and modern pharma companies have in common? There are two factors mentioned in article Embracing the Start-up Mindset in Pharma : the increasing trend [...] to pay a value-based price for value actually delivered and not just for the physical product itself the increasing...

JNJ saw sales inch 1% up to $20.4 billion in the fourth quarter of 2018. Operational sales results rose 3.3%. Domestic sales increased 1.5%, while international sales grew 0.4%. Adjusted earnings grew about 13% to $5.4 billion or $1.97 per diluted share While both Medical and Consumer segments...

I expect that Amarin will bounce back from the recent sell-off. Most of the doctors who participated in the AHA event has said that they will prescribe Vascepa and next year the biggies like Pfizer might considering acquiring Amarin...

What's the reason for Celgene going down even after beating the estimates and lifting 2018 outlook? Any thoughts? https://news.alphastreet.com/celgene-celg-stock-q3-2018-earnings/